Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against F5, Inc. due to allegations of false statements regarding its security capabilities and a significant security breach that impacted its financial performance [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in F5 to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against F5, with a deadline of February 17, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that F5 and its executives violated federal securities laws by failing to disclose the true state of the company's security capabilities [5]. Group 2: Financial Impact and Stock Performance - On October 27, 2025, F5 announced fourth quarter fiscal year 2025 results that fell significantly below market growth expectations, largely due to the security breach [6]. - The company reported expected reductions in sales and renewals, elongated sales cycles, and increased expenses related to remediation efforts [6]. - Following the announcement, F5's stock price dropped from $290.41 per share to $258.76 per share, a decline of 10.9% within two days [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SLM Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's financial health and delinquency rates [2][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in SLM to contact them for discussing legal options, particularly for those who purchased securities between July 25, 2025, and August 14, 2025 [1]. - A federal securities class action has been filed against SLM, with a deadline of February 17, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against SLM - The complaint alleges that SLM and its executives made false and misleading statements regarding the company's financial stability, particularly concerning early-stage delinquencies and the effectiveness of loss mitigation programs [5]. - A report from TD Cowen indicated that July 2025 delinquencies increased by 49 basis points month-over-month, contradicting SLM's previous assurances about normal seasonal trends [6]. - Following the TD Cowen report, SLM's stock price dropped by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [6]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to allegations of violations of federal securities laws, particularly regarding misleading statements and guidance related to the company's financial performance [4][6]. Company Overview - Agilon health, inc. is publicly traded on the NYSE under the ticker AGL [4]. - The company has faced significant challenges, leading to a suspension of its previously issued full-year 2025 financial guidance [7]. Allegations and Legal Actions - The complaint against agilon health alleges that the company and its executives made false or misleading statements, including: 1. Recklessly issuing guidance for 2025 that was unlikely to be achieved due to known industry headwinds [6]. 2. Overstating the immediate positive financial impact from strategic actions taken to reduce risk [6]. 3. Providing materially false or misleading statements about the company's business and prospects [6]. - Following the release of disappointing second-quarter results on August 4, 2025, agilon health's stock plummeted by 51.5% on August 5, 2025 [7]. Class Action Details - A federal securities class action has been filed against agilon health, with a deadline of March 2, 2026, for investors to seek the role of lead plaintiff [4]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8]. Call for Information - Faruqi & Faruqi encourages anyone with information regarding agilon health's conduct, including whistleblowers and former employees, to come forward [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, particularly related to misleading statements and guidance regarding financial performance [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in agilon health to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against agilon health, with a deadline of March 2, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that agilon health and its executives made false statements and failed to disclose significant industry challenges that would impact financial guidance for 2025 [5]. Group 2: Financial Performance and Market Reaction - On August 4, 2025, agilon health reported its second-quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [6]. - Following the announcement, agilon health's stock experienced a significant decline of 51.5% on August 5, 2025 [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - Rezolute, Inc. is facing potential legal claims following a significant drop in its stock price due to disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug [5]. Group 1: Company Overview - Rezolute, Inc. is publicly traded on NASDAQ under the ticker symbol RZLT [2]. - The company is focused on developing treatments for congenital hyperinsulinism [5]. Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug did not meet its primary and key secondary endpoints [5]. - The highest dose in the trial showed reductions in hypoglycemia events that were not statistically significant compared to placebo [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute for investors who suffered significant losses [2][4]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for failing to disclose significant issues in its infant formula business, leading to investor losses during the class period from February 27, 2023, to November 4, 2025 [2][7]. Allegation Details - The lawsuit alleges that Perrigo did not disclose the following: 1. The infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance and operational improvements [7]. 2. Perrigo needed to make substantial capital and operational expenditures beyond previously stated cost estimates to remediate the infant formula business [7]. 3. There were significant manufacturing deficiencies in the facility for the infant formula business [7]. 4. As a result, the Company's financial results, including earnings and cash flow, were overstated [7]. Financial Impact - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a significant reduction in its fiscal year 2025 outlook due to issues in the infant formula industry [7]. - The announcement included a reassessment of a previously announced investment of $240 million in the infant formula business, which was deemed "less strategic" [7]. - Following this news, Perrigo's stock price fell by $5.09, or 25.2%, closing at $15.10 per share on the same day [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [2][5]. Group 1: Legal Investigation - The law firm is looking into claims against agilon health, reminding investors of a deadline on March 2, 2026, to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that agilon health and its executives made false or misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [5]. Group 2: Financial Impact - On August 4, 2025, agilon health announced the suspension of its full-year 2025 financial guidance, leading to a significant stock price drop of 51.5% on August 5, 2025 [6]. - The company’s Executive Chair acknowledged that industry headwinds were more severe than previously anticipated, impacting the company's financial outlook [6]. Group 3: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding agilon health's conduct, including whistleblowers and former employees, to reach out to the firm [8].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly making misleading statements and failing to disclose material adverse facts about its business during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities from July 25, 2024, to October 22, 2025 [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint alleges that Integer overstated its competitive position and did not adequately disclose sales deterioration in its electrophysiology devices [3]. - The lawsuit claims that the company mischaracterized its growth drivers [3]. - The truth about the company's performance began to emerge on October 23, 2025, when it reduced its sales guidance, leading to a stock price decline of $35.22 per share, over 32% in a single trading day [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Alexandria Real Estate Equities, Inc. due to allegations of securities law violations related to misleading statements and undisclosed adverse facts about the company's Long Island City property [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Alexandria between January 27, 2025, and October 27, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Alexandria, with a deadline of January 26, 2026, for investors to seek the role of lead plaintiff [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [6]. Group 2: Financial Performance and Market Reaction - Alexandria reported third quarter earnings on October 27, 2025, which fell short of analyst expectations, showing a 5% decline in revenue and a 7% decline in adjusted funds from operation [5]. - The average occupancy rate for Alexandria decreased from 94.8% in the previous year to 91.4% [5]. - Following the disappointing financial results, Alexandria's stock price dropped over 19% on October 28, 2025 [5]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Blue Owl Capital Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed liquidity issues [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Blue Owl to contact them, especially those who purchased securities between February 6, 2025, and November 16, 2025 [1][2]. - A federal securities class action has been filed against Blue Owl, with a deadline of February 2, 2026, for investors to seek the role of lead plaintiff [2][7]. Group 2: Allegations Against Blue Owl - The complaint alleges that Blue Owl and its executives made false or misleading statements regarding the company's asset base and liquidity issues, which were not disclosed to investors [4]. - Specific allegations include that Blue Owl was facing significant pressure from Business Development Company (BDC) redemptions and was likely to limit or halt redemptions of certain BDCs [4]. Group 3: Impact on Investors - On November 16, 2025, it was reported that Blue Owl blocked redemptions in one of its private credit funds due to a merger, potentially leading to large losses for investors [5]. - Following the news of the merger, Blue Owl's stock price fell by $0.85, or 5.8%, closing at $13.77 per share on November 17, 2025, indicating a negative impact on investor value [6].